MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). We are building a broad, flexible and cutting-edge drug discovery platform based on the premise that no single RNAi technology or delivery approach can overcome the target specific and indication specific challenges of down regulating protein expression via a siRNA therapeutic. As a result, we have implemented a multi-faceted, multi-disciplinary and multi-technological approach to discovering novel and proprietary RNAi-based therapeutics we are confident will lead to clinical success.
We are employing proven RNAi technologies within a highly adaptable and cell-specific delivery platform to down-regulate specific protein expression that causes disease. This approach gives us the flexibility to fully optimize RNAi-based therapies that target a wide range of diseases based on the unique characteristics of the cells and organs involved.
3830 Monte Villa Parkway